肿瘤药学2019，Vol.9Issue(1)：14-19,6.DOI:10.3969/j.issn.2095-1264.2019.01.04
免疫检查点抑制剂在非小细胞肺癌治疗中的临床应用
The Clinical Application of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
CUI Jiandong 1ZHANG Yu 1WANG Hongzhi1
作者信息
- 1. Department of Oncology, 923 Hospatial of PLA, Nanning, Guangxi, 530021, China
- 折叠
摘要
Abstract
Platinum-based chemotherapy is the standard first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) without driver genes. But, the results of this treatment are far from satisfactory. In recent years, immune checkpoint inhibitors have shown significant antitumor activity in NSCLC. To date, the most widely studied and applied immune checkpoint inhibitors have been related to programmed death-1/ programmed death ligand-1(PD-1/PD-L1) and cytotoxic T lymphocyte-associated antigen-4(CTLA-4). In this paper, we reviewed the mechanism and clinical application of immune checkpoint inhibitors in NSCLC.关键词
非小细胞肺癌/免疫检查点抑制剂/程序性死亡因子-1/程序性死亡因子-1配体/细胞毒性T淋巴细胞相关抗原-4Key words
Non-small cell lung cancer/ Immune checkpoint inhibitors/ Programmed death -1/programmed death ligand-1(PD-1/PD-L1)/ Cytotoxic T-lymphocyte-associated antigen-4(CTLA-4)分类
医药卫生引用本文复制引用
CUI Jiandong,ZHANG Yu,WANG Hongzhi..免疫检查点抑制剂在非小细胞肺癌治疗中的临床应用[J].肿瘤药学,2019,9(1):14-19,6.
